Publication date: 2020

DOI: 10.1016/j.jaci.2020.02.001

Asthma is a severe and chronic disabling disease affecting morethan 300 million people worldwide. Although in the past fewdrugs for the treatment of asthma were available, newtreatment options are currently emerging, which appear to behighly effective in certain subgroups of patients. Accordingly,there is a need for biomarkers that allow selection of patients forrefined and personalized treatment strategies. Recently,serological chip tests based on microarrayed allergen moleculesand peptides derived from the most common rhinovirus strainshave been developed, which may discriminate 2 of the mostcommon forms of asthma, that is, allergen- and virus-triggeredasthma. In this perspective, we argue that classification ofpatients with asthma according to these common trigger factorsmay open new possibilities for personalized management ofasthma.

Тип: Article